Prevalence of IgA Anti-tissue Transglutaminase Antibody in a Cohort of Iranians Patients with Inflammatory Bowel Disease

Abstract

Background and Aims Some studies have reported the coexistence of inflammatory bowel disease (IBD) and celiac disease (CD). However, the prevalence of anti-tissue transglutaminase antibodies (IgA and IgG) and their screening value in patients with IBD is not yet clear. This study aimed to assess the prevalence of IgA anti-tTG and its potential correlation with disease status in patients with IBD.

Materials and Methods This cross-sectional study was conducted on 110 patients with confirmed IBD diagnosis at Ghaem Hospital, Mashhad, Iran. For each patient, all demographic and clinical data including age, extra intestinal manifestations, underlying diseases, types of diseases, and surgical history were collected. IgA anti-tissue transglutaminase titers were assessed by enzyme-linked immunosorbent assay.

Results None of the patients with IBD were positive for IgA anti-tTG antibodies, with a mean titer of 3.31 ± 1.3 AU/mL. Also, the mean titers were not associated with age, gender and various disease clinical features including the disease history, underlying disease, diagnosis type, extraintestinal manifestations, and surgery history.

Conclusion No significant prevalence pattern of IgA anti-tTG antibody was observed in patients with IBD. Accordingly, serological screening for CeD is not recommended in IBD patients, unless in a relevant clinical CeD suspicion.

Keywords

Celiac disease - Crohn's disease - IgA anti-tissue transglutaminase - inflammatory bowel disease - ulcerative colitis

Data Availability Statements

All data generated or analyzed during this study are included in this published article

Publikationsverlauf

Eingereicht: 01. Juni 2023

Angenommen: 24. Oktober 2023

Artikel online veröffentlicht:
27. November 2023

• References

• 1 Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. World J Gastroenterol 2022; 28 (26) 3092-3100
• 2 Ramos GP, Papadakis KA. Eds. Mechanisms of disease: inflammatory bowel diseases. Mayo Clinic Proceedings; Elsevier; 2019
• 3 Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med 2020; 383 (27) 2652-2664
• 4 Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol 2022; 19 (12) 753-767
• 5 Yu T, Xie Y, Yuan J. et al. The nutritional intervention of resveratrol can effectively alleviate the intestinal inflammation associated with celiac disease induced by wheat gluten. Front Immunol 2022; 13: 878186
• 6 Catassi C, Verdu EF, Bai JC, Lionetti E. Coeliac disease. Lancet 2022; 399 (10344): 2413-2426
• 7 Gobbi G, Mainardi P, Striano P, Preda A. Epilepsy, coeliac disease and other inflammatory bowel diseases. The Comorbidities of Epilepsy. Elsevier; 2019: 107-130
• 8 Bengi G, Cıvak M, Akarsu M. et al. Prevalance of celiac disease in patients with inflammatory bowel disease in Turkish population. Gastroenterol Res Pract 2019; 2019: 6272098
• 9 Donat E, Roca M, Castillejo G. et al; Coeliac Disease Working Group of the Spanish Gastroenterology, Hepatology, Paediatric Nutrition Society (SEGHNP). Correlation of Anti-Tissue Transglutaminase Antibodies With the Mucosal Changes and IgA Status of Children With Celiac Disease. J Pediatr Gastroenterol Nutr 2022; 75 (06) 743-748
• 10 Infantino M, Merone M, Manfredi M. et al. Positive tissue transglutaminase antibodies with negative endomysial antibodies: Unresolved issues in diagnosing celiac disease. J Immunol Methods 2021; 489: 112910
• 11 Savvateeva LV, Erdes SI, Antishin AS, Zamyatnin Jr AA. Current paediatric coeliac disease screening strategies and relevance of questionnaire survey. Int Arch Allergy Immunol 2018; 177 (04) 370-380
• 12 Gandini A, Gededzha MP, De Maayer T, Barrow P, Mayne E. Diagnosing coeliac disease: A literature review. Hum Immunol 2021; 82 (12) 930-936
• 13 Losurdo G, Di Leo M, Santamato E. et al. Serologic diagnosis of celiac disease: May it be suitable for adults?. World J Gastroenterol 2021; 27 (42) 7233-7239
• 14 Elwenspoek MMC, Jackson J, O'Donnell R. et al. The accuracy of diagnostic indicators for coeliac disease: A systematic review and meta-analysis. PLoS One 2021; 16 (10) e0258501
• 15 Chourasia S, Ahirwar S. Celiac Disease. Int J Pharm Sci Med 2021; 6: 42-72
• 16 Alkhayyat M, Abureesh M, Almomani A. et al. Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease. Inflamm Bowel Dis 2022; 28 (03) 385-392
• 17 Zhu X, Zhao X-H, Zhang Q. et al. How does a celiac iceberg really float? The relationship between celiac disease and gluten. Crit Rev Food Sci Nutr 2022; •••: 1-29
• 18 Velmishi V, Kollcaku L, Cekodhima G, Dervishi E, Cullufe P. Seronegative celiac disease presented with a pronounced abdominal distention in a 4-year-old boy-Case report and review of literature. Pediatr Ther 2020; 10: 379
• 19 Shah A, Walker M, Burger D. et al. Link between celiac disease and inflammatory bowel disease. J Clin Gastroenterol 2019; 53 (07) 514-522
• 20 Kori M, Zamir Y, Yermiyahu SO. et al. The association of Inflammatory Bowel Disease with Celiac Disease and Celiac Autoimmunity in children and adults: A nationwide study from the epi-IIRN. J Crohn's Colitis 2022
• 21 Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol 2020; 35 (03) 380-389
• 22 Roberts SE, Thorne K, Thapar N. et al. A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe. J Crohn's Colitis 2020; 14 (08) 1119-1148
• 23 Ashtari S, Najafimehr H, Pourhoseingholi MA. et al. Prevalence of celiac disease in low and high risk population in Asia-Pacific region: a systematic review and meta-analysis. Sci Rep 2021; 11 (01) 2383
• 24 Tavakkoli H, Haghdani S, Adilipour H. et al. Serologic celiac disease in patients with inflammatory bowel disease. J Res Med Sci 2012; 17 (02) 154-158
• 25 Leeds JS, Höroldt BS, Sidhu R. et al. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand J Gastroenterol 2007; 42 (10) 1214-1220
• 26 Kociszewska D, Vlajkovic SM. The association of inflammatory gut diseases with neuroinflammatory and auditory disorders. Front Biosci (Elite Ed) 2022; 14 (02) 8
• 27 Nurmi R, Pohjonen J, Metso M. et al. Prevalence of inflammatory bowel disease and celiac disease in patients with IgA nephropathy over time. Nephron 2021; 145 (01) 78-84
• 28 Almroth G, Axelsson T, Müssener E, Grodzinsky E, Midhagen G, Olcén P. Increased prevalence of anti-gliadin IgA-antibodies with aberrant duodenal histopathological findings in patients with IgA-nephropathy and related disorders. Ups J Med Sci 2006; 111 (03) 339-352
• 29 Herfarth HH, Martin CF, Sandler RS, Kappelman MD, Long MD. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2014; 20 (07) 1194-1197
• 30 Oxford EC, Nguyen DD, Sauk J. et al. Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol 2013; 108 (07) 1123-1129
• 31 Fukunaga M, Ishimura N, Fukuyama C. et al. Celiac disease in non-clinical populations of Japan. J Gastroenterol 2018; 53 (02) 208-214
• 32 Alper A, Rojas-Velasquez D, Pashankar DS. Prevalence of anti-tissue transglutaminase antibodies and celiac disease in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2018; 66 (06) 934-936
• 33 Manceñido Marcos N, Pajares Villarroya R, Salinas Moreno S, Arribas López MR, Comas Redondo C. The association between de novo inflammatory bowel disease and celiac disease. Rev Esp Enferm Dig 2020; 112 (01) 7-11 (REED)
• 34 Tse CS, Deepak P, De La Fuente J. et al. Phenotype and clinical course of inflammatory bowel disease with co-existent celiac disease. J Crohn's Colitis 2018; 12 (08) 973-980